Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)
Recruiting now
Conditions studied: Critical Illness, Acute Kidney Injury, Sepsis, Systemic Inflammatory Response Syndrome
In brief
Worldwide, the use of Extracorporeal Blood Purification (EBP) in everyday clinical practice is becoming increasingly common, particularly in critical care settings. The efficacy of most of these treatments on removal of inflammatory mediators is the main rationale behind the use of EBP in critically ill patients with multiorgan dysfunction. Nonetheless, there are still some doubts as to the clinical efficacy of bacterial toxins and cytokines removal and many clinical trials aiming at exploring the effect of EBP on long-term outcomes of septic patients have failed to demonstrate consistent results regarding 28 day- or hospital-mortality rates. The primary aim of this observational prospective web-based registry is to define the possible clusters of critically ill patients - treated with extracorporeal blood purification therapies worldwide - who are homogeneous regarding both clinical and treatment characteristics and seem to benefit the most from EBP.
Key facts
- Study ID
- NCT04580680
- Run by
- Careggi Hospital
- People needed
- 1000
- Starts
- 2020-11-01
- Expected to finish
- 2025-09-30
- Last updated by the study team
- 2025-02-12
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Azienda Ospedaliero Universitaria Careggi — Florence, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.